{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<0.0001","statisticalMethod":"Stratified Log-rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.11","upperLimit":"11.24","value":"9.40"},{"groupId":"OG001","lowerLimit":"5.09","upperLimit":"7.16","value":"5.88"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"221"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Encorafenib + cetuximab. Encorafenib: Orally, once daily. Cetuximab: Standard of care.","id":"OG000","title":"Phase 3: Doublet Arm"},{"description":"Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab. Cetuximab: Standard of care. Irinotecan: Standard of care. Folinic Acid: Standard of care. 5-Fluorouracil: Standard of care. Following protocol amendment, eligible participants could crossover to receive either triplet or doublet regimen.","id":"OG001","title":"Phase 3:Control Arm"}],"paramType":"MEDIAN","populationDescription":"The FAS for the Phase 3 portion of the study consisted of all randomized Phase 3 participants.","reportingStatus":"POSTED","timeFrame":"From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.7 weeks for doublet arm and 52.4 weeks for control arm)","title":"(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm","type":"SECONDARY","unitOfMeasure":"Months"}